• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Merus N.V.

    2/14/24 1:44:42 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    SC 13G 1 d10930277_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Merus N.V.
    (Name of Issuer)

     

     

    Common Shares, nominal value €0.09 per share
    (Title of Class of Securities)

     

     

    N5749R100
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No N5749R100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samlyn Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,412,410  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,412,410  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,412,410  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA, OO  
     
     

     

    CUSIP No N5749R100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samlyn, LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,412,410  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,412,410  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,412,410  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  
     
     

     

    CUSIP No N5749R100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Robert Pohly  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,412,410  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,412,410  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,412,410  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  
     
     

     

    CUSIP No N5749R100    

     

    Item 1. (a). Name of Issuer:  
           
        Merus N.V.  
       

     

     

     
      (b). Address of Issuer's Principal Executive Offices:  
           
       

    Uppsalalaan 17

    3584 CT Utrecht

    The Netherlands

     
           
    Item 2. (a). Name of Person Filing:  
           
       

    Samlyn Capital, LLC

    Samlyn, LP

    Robert Pohly

     
       

     

     

     
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Samlyn Capital, LLC

    500 Park Avenue, 2nd Floor

    New York, New York 10022

    United States of America

     

    Samlyn, LP

    c/o Samlyn Capital, LLC

    500 Park Avenue, 2nd Floor

    New York, New York 10022

    United States of America

     

    Robert Pohly

    c/o Samlyn Capital, LLC

    500 Park Avenue, 2nd Floor

    New York, New York 10022

    United States of America

     

     

      (c). Citizenship:  
           
       

    Samlyn Capital, LLC – Delaware

    Samlyn, LP – Delaware

    Robert Pohly – United States of America

     
       

     

     

     
      (d).   Title of Class of Securities:  
           
        Common Shares, nominal value €0.09 per share  
       

     

     

     
      (e). CUSIP Number:  

           
        N5749R100  

     

     
     

     

     


    Item 3.
      If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
         
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_]

    Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
         
       

    Samlyn Capital, LLC – 3,412,410

    Samlyn, LP – 3,412,410

    Robert Pohly – 3,412,410

         
      (b) Percent of class:
         
       

    Samlyn Capital, LLC – 5.9%

    Samlyn, LP – 5.9%

    Robert Pohly – 5.9%

         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote
         

     

    Samlyn Capital, LLC – 0

    Samlyn, LP – 0

    Robert Pohly – 0

     

        (ii) Shared power to vote or to direct the vote
         

     

    Samlyn Capital, LLC – 3,412,410

    Samlyn, LP – 3,412,410

    Robert Pohly – 3,412,410

           
        (iii) Sole power to dispose or to direct the disposition of
         

     

    Samlyn Capital, LLC – 0

    Samlyn, LP – 0

    Robert Pohly – 0

           
        (iv) Shared power to dispose or to direct the disposition of
         

     

    Samlyn Capital, LLC – 3,412,410

    Samlyn, LP – 3,412,410

    Robert Pohly – 3,412,410

     

     
     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
     
      N/A

     

     

     
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      All of the securities reported in this Schedule 13G are directly owned by advisory clients of Samlyn Capital, LLC.  None of those advisory clients may be deemed to beneficially own more than 5% of the Common Shares, nominal value €0.09 per share.

     

     

     

     

     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      Please see Exhibit B attached hereto.

     

     

     

    Item 8.
    Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A

     

     

     
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A

     

     

    Item 10. Certification.

     

        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
         
     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      February 14, 2024
      (Date)
       
         
      SAMLYN CAPITAL, LLC*
         
      By: Samlyn, LP, its sole member
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      SAMLYN, LP*
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      ROBERT POHLY*
         
      By: /s/ Robert Pohly
         

     

    * This Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G dated February 14, 2024 relating to the Common Shares, nominal value €0.09 per share, of Merus N.V. shall be filed on behalf of the undersigned.

         
      SAMLYN CAPITAL, LLC
         
      By: Samlyn, LP, its sole member
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      SAMLYN, LP
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      ROBERT POHLY
         
      By: /s/ Robert Pohly
         

     

     

     

     

     

     

     
     

    Exhibit B

    Samlyn Capital, LLC is the relevant entity for which Robert Pohly may be considered a control person.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $MRUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    11/2/2023$45.00Buy
    Canaccord Genuity
    8/21/2023Outperform
    TD Cowen
    More analyst ratings

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Merus with a new price target

      Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

      2/13/25 8:09:56 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Merus with a new price target

      Wells Fargo initiated coverage of Merus with a rating of Overweight and set a new price target of $91.00

      2/7/25 8:26:14 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Merus with a new price target

      Goldman initiated coverage of Merus with a rating of Buy and set a new price target of $73.00

      11/21/24 7:35:31 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Financials

    Live finance-specific insights

    See more
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

      -  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 -  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 -  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 -  Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla

      2/27/25 4:10:40 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merus to Present at BofA Securities 2025 Health Care Conference

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event. About MerusMerus is an oncology company de

      5/8/25 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 4:05:20 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 1:34:01 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 8:54:46 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO & PEO Lundberg Sven Ante exercised 30,297 shares at a strike of $13.40 (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      4/21/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 3,000 shares and sold $193,990 worth of shares (4,000 units at $48.50), decreasing direct ownership by 8% to 11,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:10:05 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 5,000 shares, increasing direct ownership by 71% to 12,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

      7/1/24 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

      6/15/23 7:47:06 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

      1/25/22 4:30:00 PM ET
      $INCY
      $MRUS
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MRUS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Merus N.V.

      10-Q - Merus N.V. (0001651311) (Filer)

      5/7/25 4:05:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Merus N.V.

      DEF 14A - Merus N.V. (0001651311) (Filer)

      4/24/25 4:05:39 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Merus N.V.

      PRE 14A - Merus N.V. (0001651311) (Filer)

      4/14/25 4:15:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 6, 2024 - FDA Roundup: December 6, 2024

      For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

      12/6/24 3:09:02 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care